title: Cardio-oncology: The Role of Big Data.
abstract: Despite its challenges, a "big data" approach offers a unique opportunity within the field of cardio-oncology. A pharmacovigilant approach using large data sets can help characterize cardiovascular toxicities of the rapidly expanding armamentarium of targeted therapies. Creating a broad coalition of data sharing can provide insights into the incidence of cardiotoxicity and stimulate research into the underlying mechanisms. Population health necessitates the use of big data and can help inform public health interventions to prevent both cancer and cardiovascular disease. As a relatively new discipline, cardio-oncology is poised to take advantage of big data.
authors.affiliation: Division of Cardiovascular Medicine, Duke University School of Medicine, 2301 Erwin Road, Durham, NC 27710, USA.
authors.forename: Anant
authors.initials: A
authors.lastname: Mandawat
authors.affiliation: Division of Health Services Research, Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, 509 Forest Avenue, Suite 200, Portland, MW 04101, USA.
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Williams
authors.affiliation: Division of Cardiovascular Medicine, Maine Medical Center, 22 Bramhall Street, Portland, ME 04102, USA. Electronic address: SFrancis@mmc.org.
authors.forename: Sanjeev A
authors.initials: SA
authors.lastname: Francis
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D016208:Databases, Factual; D006331:Heart Diseases / Q000209:etiology*; D006801:Humans; D033181:Information Dissemination; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D060735:Pharmacovigilance; D017741:Survivors
chemical_list: D000970:Antineoplastic Agents
keywords: Big data; Cardio-oncology; Pharmacovigilant